Wockhardt
- Market cap
- ₹ 29,250 Cr.
- P/E
- 73.4x
- P/B
- 6.1x
- 52-week range
- 1,086.7 – 2,422.3
- ROE
- 6%
- ROCE
- 8%
- Dividend yield
- 0%
- Debt / equity
- 0.45
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL 500 MCG 15T, METHYCOBAL INJ 1 ML, METHYCOBAL D 10T, HAPID 10C, PROXYFEN NANO GEL, LIVATIRA 500 10T NEW PACK, LIVATIRA INJ 5 ml, GABAWOK NT 100MG 15T, GABAWOK NT 400MG 15T, ETOBRIX 90 MG 10C, ETOBRIX TH 4 10C, ETOBRIX P 10T, GLARZEN 100IU, TERITIDE, GLIMADAY HS, GLIMADAY FORTE-2, GLIMADAY FORTE-1, GLIMADAY FORTE 3, GLIMADAY 2 mg, GLIMADAY 1 mg, MOPADAY FORTE, INOGLA, WEPOX 4000 IU 1ML, MYCORAL M, Val 450, OKERON INJ 100MCG 1ML, DARBOTIN 40, and DARBOTIN 60.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Wockhardt against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)73.4 against a typical 33.2: pricier than most peers (1st = cheapest).178th of 220
- Sales growth+25.9% against a typical +15.6% from a year earlier.65th of 197
- Share price, 3 months−1.7% against a typical −1.8%.100th of 200
- Size₹ 29,249.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).20th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A- /[ICRA]A2+ | Stable | 21 May 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 21 May 2026 | ▲ Upgrade2 notches | [ICRA]BBB /[ICRA]A3+ → [ICRA]A- /[ICRA]A2+ | — | ICRA | ₹ 2,135 Cr. | |
| 26 Aug 2025 | ▲ Upgrade | [ICRA]BBB /[ICRA]A3+ | — | ICRA | ₹ 1,085 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 2 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 10 Aug 2026 | Financial Results | Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Monday, 10th August, 2026, inter-alia, to consider and approve the Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2026. |
| 4 May 2026 | Financial Results/Fund Raising | To consider and approve the financial results for the period ended March 31, 2026 and Fund Raising |
| 10 Feb 2026 | Financial Results | Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, 10th February, 2026, inter-alia, to consider and approve the Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31st December, 2025. |
| 3 Nov 2025 | Financial Results | Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of theCompany will be held on Monday, 3rd November, 2025, inter-alia, to consider and approve theUn-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2025 |
| 8 Aug 2025 | Financial Results | Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Friday, 8th August, 2025, inter-alia, to consider and approve the Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended 30th June, 2025. |
| 29 May 2025 | Financial Results/Fund Raising | Pursuant to Regulation 29(1) (a) and (d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Thursday, 29th May, 2025, inter-alia, to consider and approve the following: (i)The Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and financial year ended 31st March, 2025; and (ii)Raising of funds by issue of Equity Shares, Equity Shares through depository receipt including Global Depository Receipts ( GDRs ), American Depository Receipts ( ADRs ), Foreign Currency Convertible Bonds ( FCCBs ), Fully Convertible Debentures ( FCDs ), Partly Convertible Debentures ( PCDs ) Optionally Convertible Debentures ( OCDs ), and / or Non-Convertible Debentures ( NCDs ) and / or other securities convertible into Equity Shares with or without warrants and/ or convertible preference shares or any security convertible into Equity Shares, or any combination of such securities in one or more tranches by way of one or more public and/ or private offerings including qualified institutional placement and/or on preferential allotment basis or any combination thereof or any other method as may be permitted under applicable law, subject to consent of Shareholders at the ensuing Annual General Meeting and such approvals and compliance as may be required, and to approve ancillary actions for the above mentioned fund raising |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 |
| Expenses | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | 737 |
| Operating Profit | 72 | 37 | −59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | 192 |
| OPM % | 10% | 5% | −8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% | 21% |
| Other Income | 24 | 8 | 10 | 30 | 9 | 8 | 15 | −77 | 21 | 15 | 67 | 31 |
| Interest | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | 52 |
| Depreciation | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | 55 |
| Profit before tax | −35 | −87 | −180 | −6 | −9 | 21 | −22 | −109 | 91 | 67 | 189 | 116 |
| Tax % | 109% | −1% | −2% | 167% | 78% | 5% | 105% | −1% | 10% | 9% | 13% | 8% |
| Net Profit | −73 | −86 | −177 | −16 | −16 | 20 | −45 | −108 | 82 | 61 | 164 | 107 |
| EPS in Rs | −5.34 | −5.76 | −11.02 | −0.91 | −1.43 | 0.86 | −1.54 | −5.54 | 4.8 | 3.63 | 10.22 | 6.52 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −3%
- 5 Years
- 4%
- 3 Years
- 8%
- TTM
- 18%
- 10 Years
- 1%
- 5 Years
- −19%
- 3 Years
- 43%
- TTM
- 983%
- 10 Years
- 10%
- 5 Years
- 35%
- 3 Years
- 101%
- TTM
- —
- 10 Years
- −2%
- 5 Years
- −3%
- 3 Years
- −1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Wockhardt | ₹ 1,904.00 | ₹ 29,250 Cr. | 73.4x | 6.1x | 6% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Habil Fakhruddin Khorakiwala
- Executive Chairman of the Board, Founder
- Deepak Madnani
- Chief Financial Officer
- Rashmi Dinesh Mamtura
- Compliance Officer, Company Secretary
- Murtaza Habil Khorakiwala
- Managing Director, Executive Director
- Huzaifa Habil Khorakiwala
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.